Clinical Trials on Essential Hypertension

Total 11463 results

Novartis

Completed

Clinical Study to Evaluate the Efficacy and Safety of Aliskiren Alone and in Combination With Hydrochlorothiazide in Patients With Essential Hypertension.

Hypertension

Germany, United States
Novartis

Completed

Efficacy and Safety of Aliskiren 300mg Compared to Irbesartan 300mg and Ramipril 10 mg in the Setting of a Missed Dose for Patients With Essential Hypertension.

Essential Hypertension

Switzerland, Germany
Novartis

Completed

Study Comparing SPP100 (Aliskiren) 150mg to Placebo and to Losartan 50mg in Patients With Mild to Moderate Essential Hypertension

Hypertension

Japan
Hanmi Pharmaceutical Company Limited

Completed

Efficacy/Safety of Amlodipine Plus Losartan Versus Amlodipine in Patients With Essential Hypertension

Hypertension

Korea, Republic of
Jeil Pharmaceutical Co., Ltd.

Completed

Clinical Trial to Evaluate the Efficacy and the Safety of Antihypertensive Tablets

Essential Hypertension

Korea, Republic of
Novartis Pharmaceuticals

Completed

Efficacy and Safety of LCZ696 Compared to Placebo in Patients With Essential Hypertension

Hypertension

China, Taiwan, Japan, Thailand, Korea, Republic of
Novartis Pharmaceuticals

Completed

A Long-term (12 Months) Safety, Tolerability and Efficacy Study of LCZ696 in Patients With Essential Hypertension

Essential Hypertension

China, Taiwan, Japan, Thailand, Korea, Republic of
Novartis Pharmaceuticals

Completed

Efficacy and Safety of LCZ696A in Patients With Essential Hypertension

Hypertension

Spain, Italy, Netherlands, United States, Denmark, Taiwan, Argentina, Germany, Russian Federation, Slovakia, Canada, Hungary, Latvia, Lithuania, Poland, Finland, France, Sweden
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Efficacy and Safety of Azilsartan Compared to Olmesartan Medoxomil in Chinese Participants With Grade I or II Essential Hypertension

Essential Hypertension

China
Boryung Pharmaceutical Co., Ltd
Asan Medical Center; Chonnam National University Hospital; Seoul National University... and other collaborators

Completed

A Valsartan 80 Mg-Referenced, Therapeutic Exploratory Clinical Study to Evaluate the Antihypertensive Efficacy of Fimasartan 30 mg During 24 Hours in Patients With Mild to Moderate Essential Hypertension

Essential Hypertension

Korea, Republic of
Daegu Catholic University Medical Center
The Korean Society of Ginseng

Completed

Effect of Korean Red Ginseng on Central Blood Pressure in Patient With Essential Hypertension (KRGCBP)

Hypertension

Korea, Republic of
Abbott
Quintiles, Inc.; Synexus; author! et al. BV

Completed

Comparison of the Effect of Eprosartan and Eprosartan Mesylate on Blood Pressure in Essential Hypertension

Essential Hypertension

Germany, Russian Federation, United Kingdom
Boehringer Ingelheim

Completed

BIBR 277 Capsule in Patients With Essential Hypertension

Hypertension
Boehringer Ingelheim

Completed

Telmisartan Compared to Losartan + Hydrochlorothiazide in Patients With Mild-to-moderate Essential Hypertension

Hypertension
PhaseBio Pharmaceuticals Inc.

Completed

Phase 1, Randomized, Double-Blind, Placebo-Controlled Exploratory Study That Will Assess the Safety, Tolerability, Pharmacokinetics and Hemodynamic Response to a Single 30 Minute Intravenous Infusion of Vasomera™ (PB1046) in Adult Subjects With Stage 1 or 2 Essential Hypertension

Essential Hypertension

United States
Bayer

Completed

High Dose BAYA1040 CR: a Long Term Extension Study

Hypertension

Japan
Chong Kun Dang Pharmaceutical

Completed

Efficacy and Safety of Carvedilol SR Versus Carvedilol IR in Patients With Essential Hypertension

Hypertension

Korea, Republic of
Novartis

Completed

Aliskiren in Combination With Amlodipine in Hypertensive Patients Not Responding to Angiotensin Receptor Blocker (ARB) Plus Amlodipine (AWESOME)

Essential Hypertension

Germany
Boehringer Ingelheim

Completed

3 x 3 Factorial Trial of Telmisartan and Hydrochlorothiazide in Patients With Essential Hypertension

Hypertension

Japan
Quantum Genomics SA

Completed

Phase I Study in Healthy Male Subjects Comparing QGC001 to Placebo

Essential Hypertension

France
Takeda

Completed

Efficacy and Safety Study of Azilsartan Medoxomil Compared to Ramipril for Treating Essential Hypertension

Hypertension

Poland, Germany, Bulgaria, Russian Federation, Serbia, Sweden, Netherlands, Estonia, Slovakia, Finland
University of Erlangen-Nürnberg Medical School

Completed

L-Arginine Metabolism in Essential Hypertension

Essential Hypertension

Germany
University of Athens

Unknown

Home Blood Pressure in Hypertension Management (HBP10)

Essential Hypertension

Greece
Boehringer Ingelheim

Completed

Using Telmisartan Alone or Combination of Telmisartan -HCTZ in the Treatment of Mild to Moderate Essential Hypertension

Hypertension
Takeda

Completed

Efficacy and Safety of Azilsartan Medoxomil Plus Chlorthalidone in Participants With Moderate to Severe Hypertension

Essential Hypertension

United States, Chile, Mexico
Fr Muller Homoeopathic Medical College
Rajiv Gandhi University of Health Sciences

Completed

Effectiveness of Viscum Album Mother Tincture as an Anti-hypertensive in Essential Hypertension

Hypertension

India
Takeda

Completed

Efficacy and Safety of Azilsartan Medoxomil and Chlorthalidone Compared to Olmesartan Medoxomil and Hydrochlorothiazide in Participants With Moderate to Severe Hypertension.

Essential Hypertension

United States, Canada
Takeda

Completed

Efficacy and Safety of Azilsartan Medoxomil and Chlorthalidone in Participants With Moderate to Severe Hypertension

Essential Hypertension

United States, Russian Federation
Bayer

Completed

Controlled Release Nifedipine and Valsartan Combination Therapy in Patients With Essential Hypertension

Hypertension

Japan
Takeda

Completed

A Safety and Tolerability Study of Azilsartan Medoxomil in Participants With Essential Hypertension

Hypertension

United States, Argentina, Mexico
Takeda

Completed

Efficacy and Safety of Azilsartan Medoxomil in Participants With Essential Hypertension

Hypertension

United States, Mexico, Argentina
RECORDATI GROUP

Completed

Efficacy and Safety of Lercanidipine and Enalapril in Patients With Essential Hypertension (FELT)

Essential Hypertension

France
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Valsartan and Amlodipine in Patients With Essential Hypertension

Essential Hypertension

Japan
Takeda

Completed

Efficacy and Safety of Azilsartan Medoxomil Co-Administered With Chlorthalidone in Participants With Essential Hypertension

Hypertension

United States
Takeda

Completed

One-Year Safety and Tolerability Study of Azilsartan Medoxomil in Participants With Essential Hypertension

Hypertension

United States, Chile, Mexico
Novartis

Completed

Safety and Efficacy of Aliskiren 300 mg, 150 mg and 75 mg in Patients With Essential Hypertension Compared to Ramipril 5 mg

Hypertension

China, India, Thailand
RostaQuo S.p.A.

Unknown

Antihypertensive Effect of Rostafuroxin Compared With Losartan in Hypertensive Patients Bearing Specified Gene Mutations

Essential Hypertension

Ireland, Italy, Poland
Novartis Pharmaceuticals

Completed

Effect of the Fixed Dose Combination Amlodipine/Valsartan on Central Aortic Blood Pressure in Uncontrolled Essential Hypertension With Amlodipine 5 mg (EXPLOR)

Hypertension

France
LG Life Sciences

Completed

Efficacy and Safety of Lercanidipine and Valsartan in Patients With Essential Hypertension

Essential Hypertension

Korea, Republic of
Boryung Pharmaceutical Co., Ltd
Covance

Completed

Fimasartan (BR-A-657) Single Oral Dose in Healthy Subjects

Essential Hypertension
Boryung Pharmaceutical Co., Ltd

Completed

A Study to Evaluate the Pharmacokinetic Drug Interaction After Oral Concurrent Administration of Fimasartan and Amlodipine in Healthy Male Volunteers

Essential Hypertension

Korea, Republic of
Boryung Pharmaceutical Co., Ltd

Completed

A Clinical Trial to Evaluate the Effect of Fimarsartan on Pharmacodynamics, Pharmacokinetics, and the Safety of Warfarin in Healthy Male Volunteers

Essential Hypertension
Hanmi Pharmaceutical Company Limited

Completed

Efficacy and Safety of Amlodipine and Losartan in Patients With Essential Hypertension

Hypertension

Korea, Republic of
Kyoto University

Completed

Efficacy and Safety of Weak Extremely Low Frequency Electromagnetic Fields in Mild and Moderate Essential Hypertension

Essential Hypertension

Japan
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company

Completed

Olmesartan Medoxomil Versus Losartan in Elderly and Very Elderly

Essential Hypertension

Germany
University of Pavia

Unknown

Valsartan and Amlodipine Compared to Losartan and Amlodipine in Hypertensive Patients

Essential Hypertension

Italy
Sankyo Pharma Gmbh

Completed

Olmesartan in Essential Hypertension

Essential Hypertension

Austria, Germany, Italy, Netherlands, Portugal, Spain, Switzerland, United Kingdom
National Center for Complementary and Integrative...

Completed

Hypertension: Prediction of Biofeedback Success

Essential Hypertension

United States
Regional Hospital Holstebro

Completed

Effects of Inhibition of NO-Synthesis on Renal Hemodynamics and Sodium Excretion in Patients With Essential Hypertension and Healthy Controls

Hypertension
Kurume University

Unknown

Efficacy of Olmesartan on Cerebral Glucose Metabolism, Vascular Inflammation and Adipose Tissue

Efficacy of Olmesartan on Cerebral Glucose Metabolism in Essential Hypertension

Japan

3

Subscribe